Please assess the completion status of the following clinical trial:

Trial Title: Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Haploidentical transplant recipients~* Informed consent signature~* Previous diagnosis of any neoplastic, metabolic or autoimmune disease~Exclusion Criteria:~* History of immune deficiency virus infection~* Hepatitis C or B virus infection~* Documented bacterial of fungal infection prior to tocilizumab infusion~* Previous use of tocilizumab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab 4 mg/kg (Type: EXPERIMENTAL): Tocilizumab 4 mg/kg IV single dose day -1 prior to haploidentical transplantation
- Tocilizumab 8 mg/kg (Type: ACTIVE_COMPARATOR): Tocilizumab 8 mg/kg IV single dose day -1 prior to haploidentical transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).